Who are IVIG infusion's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Intravenous immune globulin G, Placebo and IVIG, Intravenous ImmuneGlobulin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ivig-infusion.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

IVIG infusion — Competitive Intelligence Brief

IVIG infusion (IVIG infusion) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunoglobulin replacement therapy / Immunomodulator. Area: Immunology / Hematology.

phase 3 Immunoglobulin replacement therapy / Immunomodulator Multiple (Fc receptors, complement system, pathogen-specific antigens) Immunology / Hematology Small molecule Live · refreshed every 30 min

Target snapshot

IVIG infusion (IVIG infusion) — McMaster University. IVIG (intravenous immunoglobulin) provides passive immunity by delivering pooled antibodies from multiple donors to modulate immune responses and neutralize pathogens or autoimmune mediators.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
IVIG infusion TARGET	IVIG infusion	McMaster University	phase 3	Immunoglobulin replacement therapy / Immunomodulator	Multiple (Fc receptors, complement system, pathogen-specific antigens)
Intravenous immune globulin G	Intravenous immune globulin G	Rutgers, The State University of New Jersey	marketed	Immunoglobulin replacement therapy / Immunomodulator	Multiple (polyclonal IgG antibodies targeting various pathogens and self-antigens)
Placebo and IVIG	Placebo and IVIG	The Hospital for Sick Children	phase 3	Immunoglobulin replacement therapy / Immunomodulator	Multiple (Fc receptors, complement system, pathogenic antibodies)
Intravenous ImmuneGlobulin	Intravenous ImmuneGlobulin	University Health Network, Toronto	phase 3	Immunoglobulin replacement therapy / Immunomodulator	Multiple (IgG antibodies, Fc receptors, complement system)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunoglobulin replacement therapy / Immunomodulator class)

McMaster University · 1 drug in this class
Rutgers, The State University of New Jersey · 1 drug in this class
The Hospital for Sick Children · 1 drug in this class
University Health Network, Toronto · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). IVIG infusion — Competitive Intelligence Brief. https://druglandscape.com/ci/ivig-infusion. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab